Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16)
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Biochemistry
Reference24 articles.
1. Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529);Green;Pharmacol Ther,1990
2. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds;Herman;Adv Pharmacol Chemother,1982
3. ICRF-187 permits longer treatment with doxorubicin in woman with breast cancer;Speyer;J Clin Oncol,1992
4. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II;Tewey;Science,1984
5. DNA topoisomerase poisons as antitumor drugs;Liu;Annu. Rev Biochem,1989
Cited by 85 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Hotspots of single-strand DNA “breakome” are enriched at transcriptional start sites of genes;Frontiers in Molecular Biosciences;2022-08-15
2. Dexrazoxane for rapid extended livedo reticularis-like skin reaction due to systemic epirubicin diffusion during transcatheter arterial chemoembolization procedure for hepatocellular carcinoma;Journal of Cancer Research and Therapeutics;2021
3. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis;Free Radical Biology and Medicine;2018-12
4. A Similar Metabolic Profile Between the Failing Myocardium and Tumor Could Provide Alternative Therapeutic Targets in Chemotherapy-Induced Cardiotoxicity;Frontiers in Cardiovascular Medicine;2018-06-11
5. Topoisomerases as anticancer targets;Biochemical Journal;2018-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3